Amyloid-Journal of Protein Folding Disorders

Papers
(The H4-Index of Amyloid-Journal of Protein Folding Disorders is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
A case of asymmetric insulin-derived localised amyloid deposition associated with long-acting insulin analog administration244
Changes in the amyloid editorial board members and in editor positions233
Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies101
A second case of liraglutide-type localised amyloidosis87
Factors associated with financial toxicity in patients with transthyretin amyloidosis: results from Amyloidosis Research Consortium’s treatment affordability patient and caregiver survey66
Neurofilament light chain as a biomarker for hereditary ATTR amyloidosis − correlation between neurofilament light chain and nerve conduction study48
Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases42
Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis30
Reduction of cardiac AL amyloid deposition after complete response visualised by PiB-PET imaging29
Early cardiovascular autonomic failure in ATTRv predicts poor prognosis and may respond to disease-modifying therapy28
A novel transthyretin variant p.Val114Glu (Val94Glu) in an Italian patient with mixed phenotype hereditary transthyretin amyloidosis23
Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange22
Role of complementarity-determining regions 1 and 3 in pathologic amyloid formation by human immunoglobulin κ1 light chains20
Abnormal global longitudinal strain and reduced serum inflammatory markers in cardiac AL amyloidosis patients without significant amyloid fibril deposition18
Genetic landscape of hereditary transthyretin amyloidosis in Spain: a multicentric retrospective study17
Protease resistance of ex vivo amyloid fibrils implies the proteolytic selection of disease-associated fibril morphologies16
Clinical impact of beta-blocker withdrawal in transthyretin amyloid cardiomyopathy16
Human lysozyme inhibits the fibrillation of serum amyloid a protein from systemic AA amyloidosis16
Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay16
Factors associated with changes in serum transthyretin after treatment with tafamidis and outcomes in transthyretin cardiac amyloidosis16
0.70563697814941